07 / VISION · ECORIUM
A structure where research deepens
and industry grows
One responsible partner grows GRBM·VPMI into an industry, while the developer builds and publishes the evidence at the GRBM Clinical Center. Two roles, one goal.
In plain words
A good technology that stays inside the lab remains only a possibility; technology cannot change the world alone. So I envision a model in which all transferable rights to GRBM·VPMI pass to one responsible partner, who grows the industry in the global market.
I will step back from management and concentrate on research at the GRBM Clinical Center, publishing disease-specific papers one by one: which GRBM, made from which plant, taken how much and how, with what change. The partner builds the industry; the developer builds the evidence — two separate roles that strengthen each other.
Because 100% of the technology rights belong to the developer, the rights structure is simple. The transaction can be fast, and industrialization can start right away.
The path to building evidence
-
01
Established science
Holobiont, microchimerism, horizontal gene transfer, the regulatory role of introns
-
02
The developer's internal observations
600+ people, 2010–2026, up to 15 years of follow-up
-
03
Disease-specific clinical papers
publishing plants, doses, methods of intake and changes
-
04
Independent verification
third-party institutions confirm the results
You do not need to accept
our observations at face value
This transaction converts them into publishable clinical evidence. Original materials can be verified in person during on-site due diligence in Uljin after an NDA.
Read moreCloseFour stages investment creates, and our promise to a partner
INVESTMENT → INFRASTRUCTURE → EVIDENCE → SCALE
| Stage | Content |
|---|---|
| Investment | Secure industrialization capital through a strategic transaction with one responsible partner |
| Infrastructure | Build infrastructure for manufacturing, distribution, healthcare services and clinical evidence |
| Evidence | Convert existing internal observations into formal studies and papers, published regularly by the GRBM Clinical Center |
| Scale | Expand worldwide through the 9-Way product lines, four-level services and regional pipelines |
What a partner gains
- VPMI-CM, the black-box core catalyst — the starting point of the entire industry
- The 9-Way product platform, a plan for about 50 pipelines, and the flagship GINSENG GRBM pipeline
- Fifteen years of records on 600 people, and the developer's cooperation in converting them into clinical evidence
- From Korea to the world — the K-ECO BIO 10 ecosystem model connected to regional plant resources
The transaction
A strategic transaction for GRBM·VPMI is now officially under way. Terms are presented in a separate proposal, and the developer's personal facilities in Uljin, Gyeongsangbuk-do, remain the site of research. Interested institutions are invited to contact us through Investment & Partnership.
Terms and schedule are presented in a separate proposal after an NDA.
PARTNERSHIP · INVESTMENT
The world's first true eco-bio platform technology —
we are looking for the one partner
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.